Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
All bamlanivimab/etesevimab..
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization or ER visit 84% Improvement Relative Risk Bamlanivimab/e..  Lilly et al.  EARLY TREATMENT  RCT Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? RCT 268 patients in the USA Fewer hosp./ER visits with bamlanivimab/etesevimab (p=0.049) c19early.org Lilly, Press Release, October 2020 Favors bamlanivimab/e.. Favors control

SARS-CoV-2 neutralizing antibody program update

Lilly, Press Release, NCT04427501
Oct 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Interim results from the BLAZE-1 outpatient RCT showing improvements in viral load, symptoms and hospitalization.
Combination therapy significantly reduced viral load at day 11 (p=0.011). A greater effect is seen at day 7 (p<0.001). The proportion of patients with persistent high viral load at day 7 for combination therapy was lower (3.0 percent) versus placebo (20.8 percent), corresponding to a nominal p value of p<0.0001 without multiplicity adjustment. No emergent putative resistance variants have been observed thus far in patients treated with combination therapy.
The rate of COVID-related hospitalization and ER visits was lower for patients treated with combination therapy (0.9 percent) versus placebo (5.8 percent), a relative risk reduction of 84.5 percent (p=0.049). This was also similar to observations for LY-CoV555 monotherapy.
Combination therapy has been generally well tolerated with no drug-related serious adverse events. In LY-CoV555 monotherapy studies there have been isolated drug-related infusion reactions or hypersensitivity that were generally mild (two reported as serious infusion reactions, all patients recovered).
NCT04427501 (history)
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron Liu, Sheward, VanBlargan.
risk of hospitalization or ER visit, 84.5% lower, RR 0.15, p = 0.049, treatment 112, control 156.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lilly et al., 7 Oct 2020, Randomized Controlled Trial, USA, preprint, 1 author, trial NCT04427501 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBamlaniv../e..All
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit